Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Autor: Niemas-Teshiba R; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA., Matsuno R; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.; Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama 1-30, Japan., Wang LL; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA., Tang XX; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.; Department of Biology, Loyola University Chicago, Chicago, IL 60660, USA., Chiu B; Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA., Zeki J; Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA., Coburn J; Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, 01609, USA., Ornell K; Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA, 01609, USA., Naranjo A; Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL 32607, USA., Van Ryn C; Department of Biostatistics, Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL 32607, USA., London WB; Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Hogarty MD; Division of Oncology and Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA., Gastier-Foster JM; Institute of Genomic Medicine, Nationwide Children's Hospital and Departments of Pathology and Pediatrics, Ohio State University College of Medicine, Columbus, OH 43210, USA., Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Park JR; Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA 98105, USA., Maris JM; Division of Oncology and Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA., Cohn SL; Department of Pediatrics, Division of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA., Seeger RC; Division of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA., Asgharzadeh S; Division of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA., Ikegaki N; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA., Shimada H; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.

Publikováno v: Oncotarget [Oncotarget] 2017 Dec 15; Vol. 9 (5), pp. 6416-6432. Date of Electronic Publication: 2017 Dec 15 (Print Publication: 2018).